#New Zealand #Auckland #Aroa Biosurgery #Endoform #Venous Leg Ulcers

Aroa Biosurgery Achieves Clinical Evidence Milestone

Aroa Biosurgery, a leader in soft tissue regeneration, has reached a significant milestone by demonstrating the effectiveness of its flagship product, Endoform Natural™, in treating challenging venous leg ulcers (VLUs). Their findings are drawn from over 100 peer-reviewed studies, solidifying the company's IMG (Integrated Medical Grade) AROA ECM technology. This development marks a pivotal moment in the wound care industry, where healing difficult ulcers continues to be a challenge.

The Challenge of Venous Leg Ulcers

Venous leg ulcers are open sores that arise due to impaired blood circulation, leading to painful and persistent wounds. They pose a significant healthcare burden, and treatment success rates are low; studies indicate that only about 40% of VLUs heal after three months. The persistent nature of these wounds makes them challenging for clinicians and leads to complications such as recurring ulcers.

Real-World Evidence Study

Recently published in the International Wound Journal, a comprehensive retrospective analysis evaluated the efficacy of Endoform Natural compared to a leading reconstituted collagen dressing. The study incorporated data from 470 VLUs treated with Endoform and 360 VLUs treated with the comparator dressing across 223 wound care centers in the United States. This large-scale evaluation was particularly beneficial as it utilized real-world evidence, reflecting actual treatment practices rather than controlled environments.

Dr. Barnaby May, Chief Scientific Officer at Aroa Biosurgery, commented on the significance of real-world evidence (RWE) in assessing clinical performance. RWE studies can involve larger patient numbers, providing insights that are more representative of everyday clinical settings. This is crucial in wound care, where variability in treatment and patient characteristics is significant.

Key Findings

The study yielded remarkable results: VLUs treated with Endoform Natural healed approximately eight weeks faster than those managed with the alternative dressing. Furthermore, the likelihood of complete wound healing was significantly enhanced when Endoform was included in the treatment plan. These findings highlight not only the clinical efficacy of Endoform Natural but also its potential to reduce treatment costs and enhance the quality of life for patients suffering from chronic venous leg ulcers.

Dr. Gregory Bohn MD, one of the researchers involved, stated, "I have been using Endoform since 2012 and this recent data validates the positive outcomes I have observed in my patients with VLUs."

This study marks the second significant retrospective RWE analysis comparing Endoform Natural to other treatments, building on previous findings that showed similar improvements in managing diabetic foot ulcers (DFUs). The comprehensive nature of both studies amplifies the credibility of Endoform's proven efficacy in wound care.

In conclusion, the advancements showcased by Aroa Biosurgery underscore the critical role of innovative products like Endoform Natural in transforming the treatment landscape for venous leg ulcers and possibly other hard-to-treat wounds. These findings will guide clinicians in improving treatment methodologies, ultimately promising enhanced care for patients afflicted by these debilitating conditions.

For those interested in exploring this study further, it is available online through the International Wound Journal. This research not only paves the way for better clinical practices but also contributes valuable insights into the ongoing quest for effective wound management solutions.